Stocktoria
NEUROCRINE BIOSCIENCES INC NBIX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1996-05-23
NEUROCRINE BIOSCIENCES INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| Net margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% |
| FCF margin | 26.2% | 23.7% | 19.2% | 21.7% | 20.6% |
| Return on assets | 10.3% | 9.2% | 7.7% | 6.5% | 4.3% |
| Return on equity | 14.7% | 13.2% | 11.2% | 9.0% | 6.5% |
| Current ratio | 3.39 | 3.40 | 2.45 | 2.70 | 3.96 |
| Revenue growth | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% |
Source: SEC EDGAR filings · CIK 0000914475 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.